Dosing & Uses
Dosage Forms & Strengths
injectable solution for IV
- 20mg/mL (300mg/15mL single-dose vial)
injectable SC solution
- 100mg/mL single-dose prefilled pen
Ulcerative Colitis
Indicated for moderately to severely active ulcerative colitis
IV induction dose: 300 mg IV infusion over 30 minutes at Weeks 0, 4, and 8
SC maintenance dose: 200 mg SC (ie, 2 consecutive 100-mg injections) at Week 12, and q4Weeks thereafter
Dosage Modifications
Renal impairment
- Mild-to-moderate (CrCl 30-89 mL/min): No dosage adjustment needed
- Severe: No recommendations listed in prescribing information
Hepatic impairment
- No recommendations listed in prescribing information
Dosing Considerations
Evaluations and immunizations before initiating
- Evaluate patients for tuberculosis (TB) infection
- Obtain liver enzymes and bilirubin levels
- Complete all age-appropriate vaccinations according to current immunization guidelines
Safety and efficacy not established
Adverse Effects
>10%
Upper respiratory tract infections (8-14%)
1-10%
Injection site reactions (9%)
Arthralgia (2-7%)
Rash (4%)
Headache (4%)
Herpes viral infection (2%)
<1%
Hypersensitivity reactions (0.4%)
Frequency Not Defined
Hepatic enzyme elevations
Warnings
Contraindications
History of serious hypersensitivity reaction to mirikizumab or any of its excipients
Cautions
Hypersensitivity reactions
- Serious hypersensitivity reactions, including anaphylaxis during IV infusion, reported
- Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction
- If severe hypersensitivity reaction occurs, discontinue immediately and initiate appropriate treatment
Infections
- May increase infection risk of infection
- Do not initiate in patients with a clinically important active infection until the infection resolves or is adequately treated
- In patients with chronic infection or a history of recurrent infection, consider risks and benefits before prescribing mirikizumab
- Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur
- If a serious infection develops or is nonresponsive to standard therapy, monitor closely and do not administer until infection resolves
Tuberculosis (TB) infection
- Evaluate for TB infection before initiating
- Do not administer to patients with active TB infection
- Initiate treatment of latent TB before administering
- Consider anti-TB therapy before initiation in patients with past history of latent or active TB in whom an adequate course of treatment cannot be confirmed
- Monitor for signs and symptoms of active TB during and after treatment
Hepatotoxicity
- A case of drug-induced liver injury (ALT 18x ULN; AST 10x ULN; total bilirubin 2.4x ULN) in conjunction with pruritus was reported in a clinical trial subject following a longer than recommended induction regimen
- In the trial, mirikizumab was discontinued and liver test abnormalities eventually returned to baseline
- Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment
- Monitor thereafter according to routine patient management
- Consider other treatment options in patients with evidence of liver cirrhosis
- Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury
- Interrupt treatment if drug-induced liver injury suspected, until this diagnosis is excluded
- Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction
Immunizations
- Avoid use of live vaccines in patients treated with mirikizumab
- Medications that interact with the immune system may increase risk of infection following administration of live vaccines
- Before initiating, complete all age-appropriate vaccinations according to current immunization guidelines
- No data are available on response to live or non-live vaccines in mirikizumab-treated patients
Pregnancy & Lactation
Pregnancy
Available data from case reports of mirikizumab use in pregnant females are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes
However, monoclonal antibodies can be actively transported across the placenta, and mirikizumab may cause immunosuppression to the in utero-exposed infant
Pregnancy registry
- Monitor pregnancy outcomes in females exposed to mirikizumab during pregnancy
- Patients and healthcare providers are encouraged to call Eli Lilly and Company at 1-800-Lilly-Rx (1-800-545-5979)
Clinical considerations
-
Disease-associated maternal and embryo/fetal risk
- Risk of adverse pregnancy outcomes in women with inflammatory bowel disease (IBD) is associated with increased disease activity
- Adverse pregnancy outcomes include preterm delivery (<37 weeks gestation), low birth weight (<2,500 g) infants, and small for gestational age at birth
-
Fetal/neonatal adverse reactions
- Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester
- Because mirikizumab may interfere with immune response to infections, consider risks and benefits before administering live vaccines to infants exposed to mirikizumab in utero
- There are no data regarding infant serum levels of mirikizumab at birth and the duration of persistence of mirikizumab in infant serum after birth
- Although a specific timeframe to delay live virus immunizations in infants exposed in utero is unknown, consider a minimum of 2 months after birth because of the half-life of the product
Animal data
- An enhanced pre- and postnatal development study was conducted in cynomolgus monkeys administered mirikizumab IV during organogenesis to parturition at a dose of 300 mg/kg twice weekly (69 times the MRHD based on exposure comparisons)
- Mirikizumab crossed the placenta in monkeys
- No maternal toxicity was noted in this study
- No mirikizumab-related effects on morphological, functional or immunological development were observed in infant monkeys from birth through 6 months of age
- However, incidences of embryo/fetal loss were higher in the treated groups compared to control (6.7% [1 of 15] in controls vs 26.7% [4 of 15]), but were within the range of historical control data
- Following delivery, most adult female cynomolgus monkeys and all infants from the mirikizumab-treated group had measurable serum concentrations up to 28 days postpartum
- In infant monkeys, mean serum concentrations were ~4.8 times the respective mean maternal concentrations
Lactation
There are no data on presence of mirikizumab in human milk, effects on breastfed infants, or effects on milk production
Endogenous maternal IgG and monoclonal antibodies are transferred in human milk
Effects of local GI exposure and limited systemic exposure in breastfed infants to are unknown
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Humanized IgG4 monoclonal antibody that binds to the p19 subunit of human interleukin 23 (anti-IL23p19), inhibiting interaction with IL-23 receptor
IL-23 is a naturally occurring cytokine that is involved in mucosal inflammation and affects the differentiation, expansion, and survival of T cell subsets, and innate immune cell subsets, which represent sources of pro-inflammatory cytokines
Mirikizumab inhibits release of pro-inflammatory cytokines and chemokines
Absorption
Bioavailability: 44% (SC)
Peak plasma time: 5 days (SC)
Peak plasma concentration: 99.7 mcg/mL (IV); 10.1 mcg/mL (SC)
Trough concentration: 2.75 mcg/mL (IV); 1.7 mcg/mL (SC)
AUC: 538 mcg⋅day/mL (IV); 160 mcg⋅day/mL (SC)
Distribution
Vd: 4.83 L
Metabolism
Expected to be degraded into small peptides and amino acids via catabolic pathways in same manner as endogenous IgG
Elimination
Half-life: 9.3 days
Clearance: 0.0229 L/hr
Administration
IV Incompatibilities
Do not mix with other drugs
IV Compatibilities
0.9% NaCl
D5W
IV Preparation
Visually inspect vial for particulate matter and discoloration; solution should appear clear to opalescent, colorless to slightly yellow to slightly brown, and free of visible particles; discard if it is cloudy or there are visible particles
Use an 18-21 gauge needle to withdraw 15 mL of solution from vial and transfer to a 50-250 mL infusion bag of 0.9% NaCl or D5W
Do not dilute or infuse through same IV line with solutions other than 0.9% NaCl or D5W
Do not shake; gently invert infusion bag to mix contents
Connect IV administration set (infusion line) to prepared infusion bag and prime IV line
Start infusion immediately after preparation, or store diluted solution as described below
SC Preparation
Full 200-mg maintenance dose requires 2 prefilled pens (ie, 100 mg/pen)
Intended for use under guidance and supervision of a healthcare professional; patients (or caregivers) may self-inject after training in SC injection technique
Before injection, remove prefilled pen from refrigerator and leave at room temperature for 30 minutes
Do not shake prefilled pens
Visually inspect for particulate matter and discoloration; solution should appear clear to opalescent, colorless to slightly yellow to slightly brown, and free of visible particles; discard if it is cloudy or there are visible particles
IV Administration
Administer IV infusion over at least 30 minutes
Flush IV line (at same rate as infusion) at the end of infusion with 0.9% NaCl or D5W
Time required to flush IV line is in addition to the minimum 30-minute infusion time
SC Administration
Sites for SC injection include abdomen, thigh, and back of upper arm
Inject in different location every time
Do not inject into areas where skin is tender, bruised, erythematous, or indurated
Does not contain preservatives; therefore, discard any unused product
Do not reuse
Missed dose
- Administer dose as soon as possible
- Thereafter, resume dosing every 4 weeks
Storage
Vial and prefilled pen are not made with dry natural rubber latex
Do not freeze; do not use if it has been frozen
Do not shake
Keep in original carton to protect from light until time of use
Product is sterile and preservative-free; discard any unused portion
Unopened vial
- Refrigerate at 2-8ºC (36-46ºF)
Diluted IV solution
- If not used immediately, refrigerate at 2-8ºC (36-46ºF)
- Use diluted infusion solution within 48 total hr, of which not more than 5 hr are permitted at nonrefrigerated temperatures not to exceed 25ºC (77ºF), starting from the time of vial puncture
- Keep away from direct heat or light
- Do not freeze diluted solution in prepared infusion bag
Prefilled pen
- Refrigerate at 2-8ºC (36-46ºF)
- If needed, may store at room temperature up to 30ºC (86ºF) for up to 2 weeks in original carton to protect from light
- Once stored at room temperature, do not return product to refrigerator
- Discard if these conditions are exceeded
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.